anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Though nicotine is known to be a mild analgesic, its use in the peri-operative period to reduce postoperative opioid requirements has only recently been investigated. In nonsmokers it has been shown to reduce postoperative pain and opioid requirements in both female patients undergoing uterine surgery and male patients undergoing prostatectomy. We have recently confirmed these findings in women undergoing uterine surgery by open, laparoscopic and vaginal approaches. In this study we found a 30% mean reduction of 24 hour postoperative opioid requirements following the administration of a 3 mg dose of nicotine nasal spray. Two previous studies with perioperative transdermal nicotine found that increasing doses of nicotine and increasing serum levels of nicotine were associated with higher rates of nausea. In our study, we found that the administration of nasal nicotine was associated with a transient increase of postoperative nausea and vomiting (PONV), but this was limited to the recovery room (PACU) stay. Two studies of nasal nicotine where antiemetics were prophylactically administered did not report the incidence of nausea. In our study, antiemetics were used as rescue medications only. Thus, it is unclear if the prophylactic administration of anti-emetics would effectively counteract the transient emetogenic effect of a small dose of nasal nicotine.

Laparoscopic bariatric surgery is becoming an increasingly popular treatment of morbid obesity. We recently performed a detailed analysis of postoperative pain and opioid requirements among patients that had this type of surgery and found that among non-smokers severe pain (pain \> 7/10 on a 10 point scale) was commonly experienced (35%) despite substantial amount of postoperative opioid use (mean 68 mg oral morphine equivalents) and non-opioid analgesics in the first 24 hours. Because obesity related sleep disorders exceed 70% of patients undergoing bariatric surgery, and those disorders are exacerbated by opioids, potential therapies that could reduce postoperative opioid requirements in these patients have substantial value. Further, delayed nausea often poses a problem for these patients meeting hospital discharge criteria, and opioids used for analgesia aggravates this problem. Thus, the use of nasal nicotine could reduce the amount of opioid these patients require for postoperative analgesia. Combined with aggressive antiemetic prophylaxis against PONV, nasal nicotine could paradoxically and indirectly reduce the incidence of nausea in these patients by decreasing postoperative opioid requirements. The proposed study is a randomized clinical trial examining how nicotine affects recovery of female non-smokers undergoing bariatric surgery from general anesthesia. We will test the hypothesis that nicotine, administered in a nasal spray immediately before emergence from anesthesia, will reduce postoperative opioid requirement and postoperative pain. A secondary outcome is to assess if the routine administration of prophylactic antiemetic therapy prevents increased PONV associated with nicotine administration.
PURPOSE: The evolution of splenomegaly in patients with liver cirrhosis remains largely unknown. In this study, we followed the changes in splenic volume and established the natural course of splenomegaly. We developed an electronic circuit that simulated splenoportal circulation and identified the underlying hemodynamic mechanisms.
MATERIALS AND METHODS: This retrospective observational study included 93 patients with cirrhosis. Splenic volumes were measured in imaging studies at 6-month intervals and normalized by the ratio of each patient's maximum volume during follow-up (%Vmax). An electronic simulation model was constructed using software and realized on a breadboard.
RESULTS: Overall, the %Vmax increased from 0.77 ​± ​0.21 to a maximum of 1.00 ​± ​0.00 (p ​< ​0.001) during a median follow-up of 23 (3-162) months and then decreased to 0.84 ​± ​0.18 (p ​< ​0.001) during the next 9 (3-132) months. No interventional radiology procedure was performed to improve hepatic fibrosis and portal hypertension. The evolution of %Vmax showed single-peaked symmetry. An electronic simulation model showed that the upslope of the evolution curve was dependent on the increased intrahepatic vascular resistance and portal hypertension, whereas the downslope was dependent on the decreased portosystemic shunt (PSS) resistance.
CONCLUSIONS: Splenomegaly in cirrhotic patients aggravated over a period of 23 months and then regressed spontaneously to its initial volume. Electronic simulation of splenoportal circulation showed that splenic enlargement was due to the advancement of liver cirrhosis and portal hypertension, whereas its regression was due to the development of a PSS.
PURPOSE:To provide the titled component obtained from the cultured cell induced from the tissue or cell of a plant belonging to Hydrocotyle genus or Centella genus. CONSTITUTION:A blood-coagulating component is produced from the cultured cell (e.g. tissue-cultured callus, differentiated tissue, cultured organ, etc.) induced from the tissue or cell of a plant belonging to Hydrocotyle genus or Centella genus (e.g. Hydrocotyle sibthorpioides, Hydrocotyle maritima, Hydrocotyle japonica, etc.). Since the growth of the tissue-cultured plant is by far faster than natural plant, the objective component can be produced in a short time without being influenced with weather, on an industrial scale according to planned production schedule. It is administered at a dose of 0.01-500mg per 1ml of blood in the case of the component extracted with acetone. The blood- coagulation effect can be further improved by using the component in combination with a blood-coagulation promoting substance, fine powder of silica, kaolin, glass, etc., or a fibrous substance.
NEW MATERIAL:The phenylpiperazine compound of formula I (R is H or OH) and its salt. EXAMPLE:2-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-3-hydroxyphthal idine. USE:It has the activities to decrease the blood pressure, increase the cerebral blood flow, decrease the pulse rate, and suppress the ventricular arrhythmia caused by myocardial ischemia, and is useful as a remedy for circulatory diseases, e.g. hypotensor, antiarrhythmic, drug for ischemic diseases, peripheral vasodilator, etc. PREPARATION:The compound of formula III which is one of the compound of formula I can be produced e.g. by reacting the compound of formula II with sodium borohydride in an alcohol such as ethanol at room temperature under stirring for several hours. Another compound of formula IV which is also one of the compound of formula I can be obtained by reducing the compound of formula IIwith zinc dust in acetic acid under heating while stirring for 1-2hr.
PURPOSE: A composition containing Pleurotus eryngii var. ferulae extract or a fraction thereof is provided to prevent or relieve skin aging. CONSTITUTION: A cosmetic composition for preventing and treating skin aging contains Pleurotus eryngii var. ferulae extract as an active ingredient, which is isolated using water, alcohol of C1-C4, or a mixture thereof. A cosmetic composition for preventing and treating skin aging contains the fraction as an active ingredient. The fraction is an n-hexane fraction or ethyl acetate fraction. A health food composition for preventing and treating skin aging contains the extract as an active ingredient. [Reference numerals] (AA) Pleurotus eryngii var. ferulae extract; (BB) N-hexane fraction; (CC, DD) Water fraction; (EE) Ethyl acetate fraction
Cardiopulmonary resuscitation (CPR) is essential for the survival of cardiac arrest patients, but it can cause severe traumatic complications. In the catheterization laboratory, various physical constraints complicate the appropriate performance of CPR. However, we are not aware of reports of CPR complications in this setting. Here, we report a case of coronary artery perforation (CAP) caused by manual CPR in the catheterization laboratory. The patient, a 68-year-old woman, initially underwent successful percutaneous coronary intervention (PCI) for unstable angina. Back in the ward, the patient experienced acute stent thrombosis, which resulted in cardiac arrest, and another PCI was performed under ongoing manual CPR. Although revascularization was successful, sudden CAP occurred, leading to cardiac tamponade. Despite extensive treatment efforts, the patient died 18 hours later.Initially, the compression site of CPR was on the midline of the sternum; however, the compression site shifted to the left, to just above the left anterior descending artery, by the time that CAP was detected via angiography. This corresponded to the area where rib fractures were observed upon computed tomography, suggesting the possibility of traumatic CAP due to manual CPR. The physical constraints in the catheterization laboratory can lead to an inappropriate CPR technique and severe traumatic complications.
Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
Patients will receive Sitravatinib 100 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until progression of disease, unacceptable toxicity, death, or consent withdrawal, whichever occurs first. Treatment may be continued after progression according to physician criteria (with previous consultation with Coordinating investigator) until patients no longer receive clinical benefit.
Potassium sodium hydrogen citrate granules (MADAUS GMBH, Germany, 2.5g/packet) were administered to patients with residual stones (\>5 mm in diameter) after surgery or difficult-to-remove stones in the infrarenal calyces for a three-month intervention period. The medication was taken as follows: one packet after breakfast, one packet after lunch, and two packets after dinner. Participants were instructed to abstain from alcohol consumption, smoking, and the use of any probiotics or medications that lower uric acid levels during the therapeutic period.They were also instructed to monitor preprandial urine pH levels to maintain an effective range of 6.2-6.8.
The present invention discloses a traditional Chinese medicine for treating prostatitis, prostate hyperplasia and prostatauxe. Effective ingredients with a proportion comprise 50 grams of milk vetch, 40 grams of pilose asiabell root, 50 grams of spatholobus stem, 30 grams of red peony root, 30 grams of peach seed, 30 grams of herba artemisiae, 30 grams of red sage root, 10 grams of leech, 30 grams of cyathula root, 6 grams of eaglewood wood, 30 grams of lindera root, 40 grams of cowherb seed, 30 grams of alismatis, 40 grams of psyllium seed, 30 grams of spina gleditsiae, 20 grams of phellodendron, 20 grams of rhizoma anemarrhenae, a pair of crickets, 10 grams of radix et rhizoma rhei from Sichuan of China, 40 grams of dodder, 40 grams of privet, 5 grams of cinnamon and 30 grams of liquorice. The Chinese medicines are soaked in boiled water for 1 hour, and then, is heated to boil and simmered for 35 minutes. The traditional Chinese medicine of the present invention is obtained after filtration. Raw, cold and pungent substances are forbidden when the traditional Chinese medicine is taken, patients with non-severe conditions can recover after three doses of medicines are taken, and patients with severe conditions can recover after 5 to 6 doses of medicines are taken. The medicine can also be pulverized to powder and encapsulated, and is convenient for administration. The total effective rate of the present invention is more than 98%, and the illness is eradicated without recrudescence.
Neuroscience-based exercise approaches are a promising method that has been introduced in recent years in the treatment of non-specific musculoskeletal pain and related dysfunctions. The basis of this method is the exercises and trainings created by considering the neurobiological (changes in tissues) and neurophysiological basis (brain fog, somatosensory sensitization) of nociplastic pain in the musculoskeletal system. In the neuroscience-based exercise approach, it is aimed to reduce the increase in sensitivity in brain fog and somatosensory pathways. The main purpose is to teach the cortex that movement can be done painlessly and accurately and to alleviate the symptoms in the related tissues. It is aimed to perform the exercise painlessly and accurately by adding cognitive goals and changing the focus (14). In the literature, although there are very few studies showing that neuroscience education and therapeutic exercise combinations are effective on chronic nociplastic pain in patients with non-specific chronic neck pain, no studies examining the effects of neuroscience-based exercise approaches on gait parameters in individuals with non-specific chronic neck pain were found (15). ,16). Our study will contribute to the literature in this field and will reveal the effects of neuroscience-based exercise approaches more clearly. The aim of this study is to examine the effects of neuroscience-based exercise approaches on pain, disability and gait parameters in individuals with non-specific chronic neck pain.

Material- Methods Demographic data, gait parameters, Dizabilty level and craniovertebral angle values of individuals were evaluated with clinical data evaluation form, Spatio-Temporal Gait Analysis (LEGSystm), Neck Disability Index and photometer, respectively. The evaluations were performed 2 times before and after the treatment.
AntiBKV infused i.v. over 30 minutes. Infusion parameters may be adjusted to bodyweight so that infusion rate does not exceed 60mg/kg per hour. AntiBKV will be administered as a single infusion in Part 1 or as 4 infusions administered 4 weeks apart in Part 2 (100, 500, 1000 or 2000 mg).
Systems, methods, and computer-readable media for providing medical recommendations are disclosed. The system includes one or more data capture devices for collecting captured data that indicates a medical condition of a subject. The system also includes one or more processors and one or more non-transitory memory modules communicatively coupled to the one or more processors and the one or more data capture devices. The memory modules store machine-readable instructions that, when executed, cause the one or more processors to receive the captured data and the image data from the one or more data capture devices. The processors are further caused to complete one or more decision-making processes by analyzing the captured data and the image data. The computing device is trained to analyze the captured data indicating the medical condition of the subject and the visual data pertaining to the at least one characteristic of the subject.
This study is a multi-center prospective study. Patients who meet the indications for prostate biopsy were included in this study.The study was randomly divided into two groups, one group was transperineal free-hand biopsy; the other group was puncture stent-assisted transperineal prostate biopsy. Exploring the positive rate of puncture stent-assisted transperineal prostate biopsy 560 patients were enrolled. The main result is the positive rate of biopsy: including the detection rate of clinically meaningful prostate cancer and the detection rate of clinically insignificant prostate cancer.Secondary results include: (1)Biopsy complications include (infection, bleeding, etc.).(2)Pain score of biopsy patients (NRS score).(3) Biopsy time
Creatinine and Blood Urea Nitrogen: Increases in creatinine levels occurred in 1.2% of patients receiving ALTACE alone, and in 1.5% of patients receiving ALTACE and a diuretic. Increases in blood urea nitrogen levels occurred in 0.5% of patients receiving ALTACE alone and in 3% of patients receiving ALTACE with a diuretic. None of these increases required discontinuation of treatment. Increases in these laboratory values are more likely to occur in patients with renal insufficiency or those pretreated with a diuretic and, based on experience with other ACE inhibitors, would be expected to be especially likely in patients with renal artery stenosis [see Warnings and Precautions (5.3)]. As ramipril decreases aldosterone secretion, elevation of serum potassium can occur. Use potassium supplements and potassium sparing diuretics with caution, and monitor the patient's serum potassium frequently [see Warnings and Precautions (5.8)].

Hemoglobin and Hematocrit: Decreases in hemoglobin or hematocrit (a low value and a decrease of 5 g/dL or 5%, respectively) were rare, occurring in 0.4% of patients receiving ALTACE alone and in 1.5% of patients receiving ALTACE plus a diuretic. No US patients discontinued treatment because of decreases in hemoglobin or hematocrit.

Other (causal relationships unknown): Clinically important changes in standard laboratory tests were rarely associated with ALTACE administration. Elevations of liver enzymes, serum bilirubin, uric acid, and blood glucose have been reported, as have cases of hyponatremia and scattered incidents of leucopenia, eosinophilia, and proteinuria. In US trials, less than 0.2% of patients discontinued treatment for laboratory abnormalities; all of these were cases of proteinuria or abnormal liver-function tests.
BACKGROUND: Low back pain is the leading cause of productivity loss, imposes a significant economic burden on the patients and society. Oxidative stress is considered a critical factor in the complex pathophysiological process and pathogenic mechanism of low back pain. Adjustment dietary pattern can effectively increase antioxidant biomarkers levels within the body to reduce oxidative stress. The composite dietary antioxidant index (CDAI) serves a reliable scoring system for quantifying the potential dietary antioxidant capacity of daily diets.
OBJECTIVE: We aim to investigate the potential association between CDAI and low back pain, in order to enhance the management of low back pain through dietary guidance.
METHODS: This study included 17,682 participants from the National Health and Nutrition Examination Survey (NHANES) 1999-2000, 2001-2002, 2003-2004 and 2009-2010. The weighted logistic regression model was used to investigate the association between CDAI and low back pain, while restricted cubic spline (RCS) was employed to examine non-linear trend and cutoffs.
RESULTS: After adjusting for all confounders, the results showed that there was no significant association between CDAI and low back pain. However, individuals in the highest quartile of CDAI exhibited an 11.7% less likelihood of experiencing a low back pain than those in the lowest quartile (OR = 0.883; 95% CI [0.787,0.991], P = 0.034), and the trend test was also significant (P for trend < 0.001). RCS indicated a linear relationship between CDAI and low back pain (P for non-linear = 0.876). Gender subgroup analysis showed that this negative association was significant in the female population (OR = 0.983; 95% CI [0.968, 0.998], P = 0.027), and females in the highest quartile of CDAI were 19.7% less likely to suffer low back pain than those in the lowest quartile (OR = 0.803; 95% CI [0.682,0.945], P = 0.008). Additionally, the changes in zinc (OR = 1.009; 95% CI [1.002, 1.016], P = 0.015) and selenium (OR = 0.379; 95% CI [0.164, 0.875], P = 0.023) per milligram were independently associated with low back pain.
CONCLUSION: The fully adjusted model showed no significant association between CDAI and low back pain, but it was significant in quartiles. Meanwhile, subgroup analysis by gender revealed a negative association between CDAI and low back pain in the female population. Additionally, the findings of this study also suggested that the antioxidant diets should be studied in a dietary pattern context.
PURPOSE: A composition containing Paecilomyces cicadae mycelium extract is provided to develop anticancer immunotherapeutic agent. CONSTITUTION: A functional food composition for enhancing immune response contains Paecilomyces cicadae mycelium extract as an active ingredient. The extract is water soluble extract of Paecilomyces cicadae mycelium. The water soluble extract contains polysaccharide ingredient. A pharmaceutical composition for enhancing immune response contains the extract as an active ingredient. The daily dose of the pharmaceutical composition is 0.0001-100 mg/kg(body weight).
The iron compounds are suitable for the treatment of infectious diseases and of inflammations which are not demonstrably caused by microorganisms in human and veterinary medicine. They are Fe polymers with the general formula FenLxOy(OH)z where n is the degree of polymerisation (P), L is one or more ligands on the surface of the Fe polymers which have a spherical configuration, x is the number of ligands bonded to the polymeric molecule, y is the number of O bridges and z is the number of OH bridges. In the first step of the preparation process, the Fe core is polymerised starting from an Fe salt with a physiologically tolerated anion. In the second step of the process, a ligand substitution in the coordination sphere of the Fe atoms is carried out. Substances which have been prepared by this process show good therapeutic results in clinical tests on a number of infectious diseases. Examples of indications for their use are infectious diseases of the respiratory tract, of the lymphatic system, of the cardiovascular system, of the gastrointestinal tract and of the skin.
Oral Glucose 25% first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.